• 
• 
• 
• 
  • Ogłoszenia
  • Plan wydawniczy
  • Regulamin ogłaszania prac
  • Zasady recenzowania i recenzenci
• 
• 
• 
• 

Wydanie 2/2007

Zastosowanie Avastinu (bewacyzumab) w leczeniu cukrzycowego obrzęku plamki

Avastin Use in the Diabetic Macular Oedema (DMO) Treatment

Małgorzata Zaraś, Anna Skłodowska, Jerzy Szaflik

Katedra i Klinika Okulistyki II Wydziału Lekarskiego Akademii Medycznej w Warszawie Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie Kierownik: prof. dr hab. n. med. Jerzy Szaflik

Summary: Diabetic retinopathy is one of the serious complications of diabetes mellitus, and leading cause of blindness. There are several therapeutic options in the Diabetic Macular Oedema treatment (pharmacotherapy, laser therapy, vitrectomy). Recently new intravitreal drugs are used in the treatment of eye diseases caused by increased level of Vascular Endothelial Growth Factor (VEGF). Specific inhibition of the angiogenic, vasoactive, and permeability-inducing protein VEGF is possible by Macugen, Lucentis and Avastin. Efficacy and safety of intravitreally administered bevacizumab (Avastin), a humanized monoclonal anti-VEGF agent have been assessed in many off-label, short series trials, in AMD and diabetic patients. Maintenance of the effect of bevacizumab and its safety following repeated and prolonged administration have to be investigated in well-controlled studies.

Keywords: Diabetic Macular Oedema, Diabetic retinopathy Angiogenesis, Laser therapy, Vitrectomy, Bevacizumab

powrót